While it's an issue that's not limited to the pharmaceutical industry, miscommunication between the "doers" - those actually performing clinical trials - and the "planners," who set and monitor the budget, is particularly prominent. While research and development in a non-pharmaceutical business can often be put on indefinite hold while funding is secured, clinical trials don't share that luxury. Variables such as timing, resources, and the ability to make adjustments if obstacles arise are freedoms all crucial to a given trial's success. This means, in turn, that "holding" isn't really a viable option. So how can the behind-the-scenes program teams work in tandem with those on the front lines?Read More
CBI Scene Blog
To say that global reporting requirements are constantly changing is something of an understatement, particularly as new markets around the world continue to emerge. As a result, many industry professionals are concerned about their own ability to keep up with and be aware of all new compliance requirements around the world - even if their businesses are based primarily within the United States.Read More
Over the past few years, three major themes have been driving change across our community of life sciences meeting and event professionals.
As Millennials have become the dominant demographic, we’ve begun redesigning events to meet their expectations. As leading global events – such as C2 Montreal and Dreamforce – have reconceived their experiences, we’ve entered a “festivalization” era for meetings and events. Finally, the landscape of event technology providers has grown 70% in the last few years, ushering in new tools for meeting organizers and attendees.
These three themes have, in turn, pushed meetings and events into the forefront of emerging technology.
In 2016, virtual reality and augmented reality drove attendee delight and provided new mechanisms for learning and development.Read More
In the harsh, overhead light of the ER the ICU doc turned his attention away from my daughter to direct his gaze upon me. Two other doctors flanked him on each side. I felt overmatched. I hadn’t slept for two nights and it was probably now around 3AM of the third night. I looked back at my 12 year-old daughter, Talia, lying semi-reclined, her little body engulfed by the giant hospital bed. A clear, plastic mask covered nearly all of her face, save for her blue-green eyes and honey-colored hair. She was asleep. Finally. Her cheeks pink, her breathing less labored. An aura of purple light surrounded her.
The flu was raging through her body, making it difficult to breathe or even hold her head up. Already weakened by a rare neuromuscular disease known as CMT4J, the doctors were concerned Talia may need intubation—a tube placed into her windpipe to take over for her breathing. At the very least, she would need time on a bipap machine to help both push air into her lungs and pull it back out again. CMT4J had even stolen her muscles used for breathing.Read More
Text, tweet, post, snap - the millennial generation professional is a master of social media presence, internet research, and online connectivity. But networking and connection is just as important face-to-face as it is in pixels. Ideally, as we move toward to a more tech-centric society, we want to utilize both the digital and physical components of business to reap the benefits of both worlds.Read More
When a consumer depends on something important - test results, medication, medical advice - they often feel vulnerable or anxious about the next step in the process. Suddenly, a routine customer service interaction, such as a question about shipments, becomes another potential point of anxiety. It's important that companies in the bio and pharma industries have the right individuals at that juncture, ready and willing to guide the apprehensive consumer to the solutions he or she needs to feel comfortable and respected.Read More
Comprehensive risk assessments always seem to make it onto a to-do list, but end up being considerably more difficult to take off of that same list. They take time, effort, and resources - the trinity of what runs competitive businesses in the pharmaceutical industry. It can be tempting to keep pushing them off, involving yourself in another one of the endless checkboxes to take care of - but that's a very bad idea. The very nature of risk assessments is to prevent that looming, nasty, "what if" that could derail your projects or dismantle your clinical trials. It's finding the leak before the pipe bursts, or detecting the first wisp of proverbial smoke before a fire can start in earnest. In other words, neglecting to iron out a regular schedule of risk assessment reports could have disastrous consequences.Read More